Digest Network Come funziona
Network
/
Società
Am
Non verificato

Amphista Therapeutics

Di cosa scriviamo

Annunci EconomiciBiotecnologiaMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

17 comunicati stampa

Guarda tutti i comunicati
24/04/2026
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Medicina Salute Benessere
Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
20/04/2026
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
23/03/2026
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
18/03/2026
Biotecnologia
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics appoints Louise Modis Ph.D. as CEO and Patrick Kelly M.D. as CMO and provides a business update as the Company prepares to file IND application for AMX-883
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
26/02/2026
Biotecnologia
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys® platform is delivering Targeted Glue™ degraders using novel E3 ligases into the clinic
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
07/12/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
25/11/2025
Biotecnologia
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics announces new AMX-883 data to be presented at the ASH Annual Meeting and Exposition and provides a business progress update
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
28/10/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
27/10/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
23/10/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0